Diphenhydramine hydrochloride veterinary-grade API for tablets, injections, capsules, powders, granules, premixes, and solutions is the hydrochloride salt of 2-(benzhydryloxy)-N,N-dimethylethylamine, an ethanolamine H1-receptor antagonist with molar mass 291.82 g/mol and molecular formula C₁₇H₂₁NO·HCl. The INN is diphenhydramine hydrochloride; Benadryl is a registered trademark of the branded product and not a separate chemical entity. The material is supplied as a white or almost white crystalline powder and is controlled against the USP Diphenhydramine Hydrochloride monograph and the corresponding Ph. Eur. monograph. Its solubility is described in pharmacopeial descriptive terms as very soluble in water, freely soluble in ethanol, and practically insoluble in non-polar solvents. That solvent profile governs the choice of aqueous granulation fluid, liquid oral vehicle, and parenteral dilution system. The veterinary grade is a specification family rather than a single physical entity: milled crystalline material for direct compression and encapsulation, fine controlled fraction for aqueous suspensions, sieved granule fraction for premixes, and low-endotoxin grade for injectable compounding. The chemical identity of all these grades is the same as human diphenhydramine HCl, but the release testing, particle-size distribution, and documentation are aligned with veterinary route requirements. The product is not a sterile API on receipt; sterility is achieved downstream by aseptic filtration or terminal sterilization where stability permits.

Because veterinary dosage forms range from 0.1 wt% loaded chewable tablets to 10–25 wt% oral solutions and medicated feed premixes, the API vendor grade must be selected for the unit operation and not by compendial purity alone. A direct-compression tablet line using a gravity-fed rotary press is more sensitive to particle-size mismatch than a liquid manufacturing line; an injection line is more sensitive to endotoxin and particulate burden. The following specifications and processing boundaries define grade suitability.

What analytical release parameters define veterinary-grade diphenhydramine HCl?

Release of the veterinary API should follow the receiving controls of 21 CFR 211.84 and the documentation requirements of 21 CFR 211.194. Identification is performed by infrared absorption and by HPLC retention time concordance with a United States Pharmacopeia reference standard. Assay on the dried basis is determined by HPLC using an aqueous phosphate buffer/methanol mobile phase; the acceptance criterion is 98.0–102.0% on the dried basis. Loss on drying is measured at 105 °C under USP <731>, with a typical limit of ≤0.5% because the monohydrate is not the intended form. Residue on ignition under USP <281> is limited to ≤0.1%. Related substances are monitored by a separate HPLC impurity method, with unspecified impurities limited to ≤0.10% and total impurities to ≤0.5% under ICH Q3A-style thresholds, unless the veterinary marketing authorization specifies tighter limits. Residual solvents follow VICH GL18, which incorporates the ICH Q3C solvent classification; methanol, if used in recrystallization, is controlled at ≤3000 ppm by headspace GC under USP <467>. Bacterial endotoxins are not a uniform requirement for all grades; the low-endotoxin injectable grade is tested by kinetic chromogenic LAL under USP <85> using a lot-specific limit derived from the final injectable dose. Non-sterile solid oral grades are tested for microbial enumeration and absence of specified organisms under USP <61> and USP <62>, with acceptance levels appropriate to the intended route.

Stability studies are expected to include the same HPLC methods under forced-degradation conditions: acid hydrolysis, base hydrolysis, oxidative stress with 3% hydrogen peroxide, thermal stress at 60 °C, and photostability per ICH Q1B. In diphenhydramine HCl, oxidative stress generates benzhydrol and benzophenone-related degradation products that must be resolved from the main peak; the HPLC method therefore requires a C18 column with a particle size of 5 µm or smaller and a gradient capable of separating polar early-eluting benzophenone derivatives. The stability-indicating nature of the method is verified by peak purity using diode-array detection. For veterinary premix applications, ion-pair chromatography may be necessary when extracting diphenhydramine from complex feed matrices, and extraction recovery must be demonstrated at 0.05–2.0 g/kg feed. Stress data supporting the analytical method are required under 21 CFR 211.194(c).

Granulation and low-dose blend uniformity limits in solid veterinary dosage lines

Diphenhydramine HCl veterinary tablets are often formulated at low drug mass fractions between 0.5 wt% and 2.0 wt%. At these levels, minor electrostatic charging or particle-size mismatch between API and excipients can produce content uniformity failure during compression. Dry blending in a V-blender or bin blender under relative humidity below 20% tends to increase electrostatic adhesion of API to stainless steel vessel walls, causing assay drift between the start and end of the batch. The milled crystalline grade for solid oral products is therefore specified with a D50 near 100–150 µm, and 0.25–0.5 wt% colloidal silicon dioxide is often used to reduce charge. Scored tablets and chewable tablets tend to use direct compression when the tablet mass exceeds 150 mg. At tablet mass below 100 mg, dusting and API loss to the tablet press become measurable; a pre-blend step with API and 10–20% of the total excipient is then required.

Wet granulation in a high-shear mixer with an impeller tip speed of 5–8 m/s and water or a binder solution provides a more robust distribution; the endpoint is judged by power-draw inflection and visual break-up of large agglomerates. After drying in a fluid-bed at inlet air temperature below 60 °C to minimize impurity formation, the granules are milled through a 0.8–1.5 mm screen. Content uniformity is tested under USP <905>; for low-dose tablets, the acceptance value is ≤15.0, but veterinary products intended for multiple species may require independent validation for each target weight. Dissolution testing under USP <711> with 0.1 N hydrochloric acid or water is used to detect over-wetting or hydrophobic excipient effects; the time point and Q value are product-specific.

Parenteral and solution-grade material introduces controls not required for oral granules. The low-endotoxin grade is not sterile API; it is a controlled-particulate, low-bacterial-endotoxin crystalline powder intended for aseptic filtration during filling. A 0.22 µm PVDF or PES membrane filter is used in barrier isolator or laminar airflow filling lines compliant with EU GMP Annex 1 and 21 CFR 211.113(b). The final aqueous solution is commonly adjusted to pH 4.0–6.5; multidose vials may contain benzyl alcohol at 0.9–1.5% or phenol as preservative. Terminal sterilization at 121 °C for 15 min may be possible, but only after degradation studies demonstrate oxidation breakdown products remain below ICH Q3B thresholds. Aseptic filtration is selected when the formulation is not terminally sterilized. Endotoxin limits for the finished injection are calculated from the maximum labeled dose per kilogram and the target-species endotoxin limit; the bulk API limit is therefore derived, not a single fixed compendial value. Particulate matter in the finished injection is controlled by USP <788>. The API contributes low particulate burden when the manufacturer avoids post-crystallization hammer milling and uses closed transfer, but downstream filtration remains necessary. Powders for reconstitution and oral solutions are manufactured from the same crystalline base and do not require the parenteral particulate and endotoxin controls; instead, pH stability, preservative efficacy under USP <51>, and dose uniformity in multidose containers become critical.

Oral solutions and syrups present solubility-masked stability problems. Diphenhydramine HCl at concentrations between 1.0 and 2.5 mg/mL is readily soluble, but preservatives such as parabens may partition into flavoring oils, reducing preservative efficacy. The pH is adjusted to 4.0–6.5, and preservative efficacy is tested under USP <51>. In dry powders for reconstitution, the API is dry-blended with sucrose or dextrose and filled by volume; dose uniformity requires that particle-size segregation be minimized by using a coarser carrier and controlled humidity below 40%.

For medicated feed premixes, the dominant processing risk is segregation from carrier particles. A sieved diphenhydramine HCl granule fraction between 150 µm and 710 µm adheres more uniformly to lactose monohydrate, wheat middlings, or corncob carriers than a micronized fraction, which tends to dust and separate during auger transfer. Horizontal ribbon or paddle mixers are used; if a liquid binder is required, 2–5% mineral oil or molasses is sprayed onto the carrier before API addition to improve adhesion and reduce cross-contamination. Sampling after 5, 10, and 15 min of mixing is required to establish blend uniformity under production-scale mixer load, because published data for species-specific feed matrices is limited. The uniformity of diphenhydramine in feed is not governed by USP <905>; the test is based on substantially smaller analytical aliquots and requires method recovery verification over the intended concentration range, typically 0.05–2.0 g/kg feed.

When veterinary diphenhydramine HCl is substituted for other antihistamine APIs

Diphenhydramine HCl differs from loratadine, cetirizine dihydrochloride, and chlorpheniramine maleate in chemical class, solubility, receptor binding, and manufacturing behavior. It is not interchangeable with those agents on an equal-mass basis, and it is not interchangeable with diphenhydramine citrate or tannate without salt correction. The free-base correction factor for diphenhydramine hydrochloride is 0.875; therefore a 25 mg quantity of diphenhydramine HCl contains approximately 21.9 mg of diphenhydramine free base. In tableting, diphenhydramine HCl is highly water-soluble and can be dissolved in the granulating fluid, whereas loratadine is practically insoluble in water and often requires surfactant or solvent processing. Cetirizine dihydrochloride is also water-soluble but has a different pH stability window and a less sedating clinical profile in most species. A veterinary formulation cannot assume bioequivalence from dissolution similarity alone because first-pass metabolism differs among dogs, cats, horses, and food-producing species. Compounded veterinary preparations made from crushed human tablets are not equivalent to a dedicated veterinary API lot that provides pre-validated particle-size distribution, residual solvent, microbial, and endotoxin documentation under 21 CFR 211.84 and VICH GMP guidance. The dedicated grade also permits a manufacturer to assign a retest interval based on stability data, whereas repurposed crushed tablets lack such process validation.

Storage and handling boundaries are set by compendial stability and processing observations. The API should be stored in tightly closed containers at controlled room temperature, protected from light and moisture. If the storage relative humidity exceeds 60%, surface moisture may cause powder to fuse in hoppers or feed screws, producing weight variation on encapsulation and compression equipment. Exposure to direct light in solution should be avoided because diphenhydramine HCl solutions can photodegrade to benzophenone-related impurities; amber glass or opaque high-density polyethylene containers are used for oral liquid and injectable packaging. For premix and granule operations, storage silos and transfer lines should be grounded to limit electrostatic segregation. The choice of antioxidant and chelator in injectable and oral solution formulations must be based on forced-degradation studies; published data for all veterinary species and container-closure systems is limited, and development trials should use the final packaging configuration under ICH Q1A-style accelerated conditions.